Isolation and Production of Cells Suitable for Human Therapy: Challenges Ahead  by Ährlund-Richter, Lars et al.
Cell Stem Cell
PerspectiveIsolation and Production of Cells Suitable
for Human Therapy: Challenges Ahead
Lars A¨hrlund-Richter,1 Michele De Luca,2 Daniel R. Marshak,3 Megan Munsie,4 Anna Veiga,5 and Mahendra Rao6,*
1Department of Woman and Child Health, Karolinska Institutet, 171 76 Stockholm, Sweden
2Department of Biomedical Sciences, Centre for Regenerative Medicine, University of Modena and Reggio Emilia, 41100 Modena, Italy
3PerkinElmer Inc., Shanghai 201203, China
4Government Affairs and Policy Australian Stem Cell Centre, Clayton, Victoria 3800, Australia
5Banc de Linies Cel$lulars, Centre de Medicina Regenerativa de Barcelona CMR[B], 08003 Barcelona, Spain
6Invitrogen, Frederick, MD 21704, USA
*Correspondence: mahendra.rao@invitrogen.com
DOI 10.1016/j.stem.2008.11.012
Considerable practical hurdles must be overcome prior to the broad application of stem cell therapies. We
outline challenges that may vary across different models of cell therapy, including the following broad
concepts: issues related to the sourcing of material, and issues related to product manufacturing, shipping,
storage and tracking, and standardization.Introduction
Cell therapy has been available for several decades. Most of this
therapy was and continues to be autologous therapy typified by
bone marrow transplants. Current autologous therapies include
hematopoietic cell therapies as well as mesenchymal, cartilage,
epithelial, and limbal stem cell therapy. Clinical allogeneic stem
cell therapy currently utilizes mainly unrelated bonemarrow, um-
bilical-cord blood, or mesenchymal stem cell (MSC) transplants
(Gluckman et al., 1989; Fanning et al., 2008; Le Blanc and Ring-
de´n, 2006) and also includes skin substitutes used as temporary
dressings (reviewed by Yu et al., 2008). Transplantation of skin is
likely the oldest tissue replacement therapy by far, in that the first
documented allo- and autologous skin grafts were performed
in ancient India (600 B.C.) and later in Europe (1400–1800s) to re-
pair injuries and tissue destruction caused by syphilis (Yu et al.,
2008, and references therein).
Trials of primary cell therapy using allogenic pancreatic islets
(reviewed by Otonkoski et al., 2005), or dopaminergic neurons
derived from fetal tissue (reviewed by Astradsson et al., 2008),
have reported promising results, and both human embryonic
stem cell (hESC)- and human neuronal stem cell (hNSC)-derived
cell transplants are in some cases close to approval. In addition,
with the growth of medical tourism, many unregulated cell
therapies are being undertaken worldwide (Lau et al., 2008).
Irrespective of the origin chosen, stem cells are thought to en-
hance repair by one or more mechanisms. These include direct
replacement of diseased/damaged cells in tissue; differentiation
into the desired cells/tissues; and trophic benefits—either via se-
cretion of growth factors to stimulate local stem cell growth and
differentiation, or via homing signals that recruit distant stem
cells, or via signals that modulate the immune system (reviewed
in Magnus et al., 2008).
What hasbecomeclear over the last decade is that nouniversal
cell type or generalized method of cell delivery will be universally
applicable for therapy. Therewill therefore nodoubt be regulatory
issues that are specific to a particular cell type, particular modal-
ity of action, and specific method of delivery. However, in the
case of cells produced in a central facility to yield single lots20 Cell Stem Cell 4, January 9, 2009 ª2009 Elsevier Inc.used to treat a relatively large number of patients, some common
regulatory issues will be in play (irrespective of the specific cell
type). We expect that allogeneic cell therapy will require cells,
likedrugs, tobe ‘‘manufactured.’’ Indeed, cell therapy regulations
have evolved from the regulations developed to oversee small
molecule manufacture. We expect that manufactured products
will require preclinical testing followed by evaluation in clinical
trials. On average, small molecule drug development takes 10–
15 years, and we estimate that validated stem cell therapies will
arise in approximately the same time frame.
Three main models of cell therapy are likely to emerge: (1)
a personalized medicine/point of contact model, in which cells
are harvested from the same or a related individual and undergo
minimal or extensive manipulation before being delivered to the
recipient; (2) a banking model, akin to the existing umbilical-cord
blood system and involving indeterminate periods of storage and
minimal processing; and (3) a manufacturing model, whereby
cells are produced in a central facility and a single lot is used
for a relatively large number of patients, as in existing drug deliv-
ery paradigms. Each model is likely to require distinct regulatory
regimes, as determined in part by a range of pertinent issues
concerning sources of material; manufacturing; shipping, stora-
ge,and tracking; and issues related to combining cell and gene
therapy.
Source Issues
The prospects for controlling stem cell sourcematerials are quite
different when comparing the manufacturing of cell transplants
versus drugs but perhaps common to all modalities of cell ther-
apy. These differences are related mainly to the challenges of
identifying the presence of potential infectious agents, acquisi-
tion of genetic abnormalities, and the intrinsic variability of bio-
logics (reviewed in Kirouac and Zandstra, 2008). Beyond these
points, however, it is also important to highlight the principle of
ownership of donated material. Guidelines for blood donation,
organ donation, and cell-line creation from tumor samples have
been quite explicit: once a human biological sample is donated,
then commercial rights belong to the investigator or hospital
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with appropriate donor consent (see, however, Harris et al.,
2006). Courts have generally upheld these regulations, and the
history of litigation over ownership of the HeLa cell line is perhaps
a good example of the legal viewpoint (Masters, 2002). It can be
expected that a similar situation will prevail in the case of hESCs.
Ownership issues also arise in terms of intellectual property, pat-
ents, and ownership of stem cells collected from minors, as in
umbilical-cord blood donations. Cell banks have already begun
grappling with these issues.
There are several source issues relevant to the manufacturing
process, some which are particularly pertinent to cell therapy. A
major issue of concern is traceability, arising from a need to bal-
ance confidentiality requirements to ensure donor anonymity,
and the regulatory requirements for availability of important infor-
mation, e.g., the ability to trace and return to the source for any
additional data. National interpretations of these issues will have
major impact on regulatory constraints and the content of
consent documents in different countries.
A second and equally important issue in terms of sourcing
material is that, with time, new uses of donated material may
be developed. Given the novelty of the field, such development is
not unlikely. Recently, researchers working with umbilical-cord
blood reported the presence of multiple populations of ESC-
like and other pluripotential stem cells supposedly capable of
giving rise to not only hematopoietic but also epithelial, endothe-
lial, and neural tissues (Harris and Rogers, 2007). The question of
whether one has to obtain new consent or whether the use of
such cells is covered by the existing agreement needs to be clar-
ified. Similarly, there are rapid advances being made in genetic
typing and disease prediction that may make some cell sources
more useful than others. It may then be necessary to return to
original donors to request additional material and/or information.
It will also be important to determine how the source material
should be stored to allow for a small amount of material to be
available for such unforeseen but important scientific consider-
ations, such as novel testing and typing. Sourcing therefore
requires considerable planning, particularly in preparing consent
documentation, in the discussion with prospective donors and in
ensuring that the project satisfies regulations that define current
tissue procurement practices.
A particularly contentious issue relevant to proper sourcing of
cellular material is the question of determining equivalence of
source. Defining equivalence in drugs is relatively straightfor-
ward, and the generic drug industry is an example of the in-
creased competition and cost reduction that is possible because
guidelines on establishing equivalence exist. How this equiva-
lence will be established for cells is, however, a much more
difficult process, and there is little guidance available from the
regulatory authorities. Are MSCs harvested from one source
equivalent to MSCs harvested from another site or tissue, or
by a different process? If these populations are not considered
equivalent, then safety, dosing, and other processes will have
to be validated with each equivalent cell, rather than being based
on a common set of data. Likewise, there are extensive data
available on dopaminergic neurons derived from fetal tissue,
but are these neurons similar to hESC-derived dopaminergic
neurons? Although they may appear to be identical in biological
terms to fetal tissue-derived neurons, and perhaps even judgedfunctionally equivalent, this conclusion may not be true in the
eyes of the regulatory authorities. As one can imagine, this deci-
sion would have significant implications on the time line in which
a therapy might reach the clinic.
A related issue for cell therapy is variability of biological
sources. In the currently used standard bioproduction model,
variability in allogenic therapies is alleviated by preparing a single
‘‘master bank’’ of validated clinical grade cells from which a
‘‘working bank’’ of cells is established (see Figure S1 available
online). Cells from thisworking bank are subsequently processed
to generate the cell type of choice for therapy. However, in many
cell therapies (particularly when using autologous manipulated
cells, or where the source is limited), preparation of a master
bank is not possible, and the problems of variability of biological
sourcesmustbe successfully addressedbefore suchcell therapy
will be a viable, generalized clinical process.
Different Regulations Pertain to Different
Therapeutic Models
As discussed above, cells processed from donated tissue
samples will be governed by a set of principles that depend in
part on the degree of manipulation and the potential method of
delivery. Thus, a critical decision for a researcher entering this
field is to determine which specific guidelines apply to the mo-
dality of therapy being envisaged. Equally important is to ascer-
tain whether other cells used for the same indication fall under
similar or different guidelines. This evaluation will determine
how one proceeds and the cost entailed with the development
process.
Cells that are destined for allogeneic use will likely be manu-
factured in a centralized facility and regulated in the same way
as other biological agents (Figure S2). Manufacturing will involve
the expansion and differentiation of cells from the working bank
(Figure S1). This approach will likely require genetic manipula-
tion, selection, and/or exposure to possibly ill-defined reagents.
Irrespective of the specific culture steps, manufacturing pro-
cesses must adhere to current good manufacturing practice
(cGMP) and other relevant regulations (Figure 1). These regula-
tions are codified in the United States by the U.S. Food and
Drug Administration (FDA), and by The European Medicines
Agency (EMEA) in the European Union (see Table 1). Other coun-
try-specific regulations can be found at the appropriate regula-
tory authorities. It is also important to note that regulations
involving the use of instruments in the manufacturing process,
or devices used to deliver cellular products, are regulated in the
US by the Center for Drug Evaluation and Research (CDER),
a separate division of the FDA. Depending on the classification
of the device and the relative novelty of use, additional documen-
tation to demonstrate compliance to GMP manufacturing
processes may be required.
On the other hand, it is not yet clear what regulations will
govern modalities of cell therapy that undergo minimal process-
ing, such as cord blood. As discussed above, several modalities
of therapy are proposed ranging from autologous, minimally
manipulated cells to the allogenic, extensively processed, cen-
tralizedmodel of therapy. Regulations relevant to this wide range
of modalities are beginning to be discussed and take into
account both the potential benefits and the corresponding levels
of risk associated with each modality.Cell Stem Cell 4, January 9, 2009 ª2009 Elsevier Inc. 21
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function’’) in cell therapy is in some countries used as a criterion
for regulation. In the US, different sections of the Public Health
Safety Act regulate homologous and nonhomologous uses
(Halme and Kessler, 2006). Nonhomologous use requires the
submission of an investigational new drug (IND) application to
the FDA before studies involving humans are initiated. For exam-
ple, use of bone marrow samples for cardiac repair (i.e., ‘‘nonho-
mologous’’ use) is held to different standards than if the same
cells were used for marrow replacement (‘‘homologous’’ use).
However, since the true function of most stem cells has yet to
be fully elucidated, the definition of homologous use is imprecise,
making regulations difficult to interpret or implement. Further-
more, it is difficult to imagine how off-label use can be regulated.
Challenges aside, this regulatory distinction is well intentioned
and could be considered responsible for providing some
standardization in the US.
In the EU, homologous versus nonhomologous transfer is
not considered a criterion for regulation. Instead, the level of
regulation is proportional to the degree of risk originating from
the level of manipulation and/or possible contamination of path-
ogens. This difference in regulatory criteria can lead to varia-
tions in international manufacturing processes. Local regulatory
concerns may also impact the choice of cell type used in a given
product, rather than being directed by a medical/scientific
rationale.
Given the inherent variability of cells, coupledwith the stringent
requirements of establishing manufacturing uniformity, regula-
tions for personalized medicine will no doubt have to be flexible.
It is also important to note that developing cell therapies will have
to adhere to the guidelines of the country in which the cells are
manufactured, as well as the country in which the product will
be made available for use or sale.
Figure 1. Bioproduction Model
A model of the GMP process is shown. A process
is developed, vendors and material used in the
process are qualified, and tests are developed to
assess the quality of the received material. The
process is refined, standard operating procedures
are established, and a facility and processes are
validated by multiple production runs.
Manufacturing Issues Key to
Allogenic and Extensively
Manipulated Models
The essential concept of GMP is to en-
sure that a production process is reliable,
reproducible, and transferrable to any-
one familiar with the specific techniques.
Control processes and tests ensure that
an unsafe product is not released. Quality
control protocols were established and
have long been in place for drug manu-
facturers, and they were subsequently
modified to encompass production of
biologics such as peptides, antibodies,
and vaccines and now also to accommo-
date the cell-manufacturing process. It
is important for cell therapy investigators and regulators to
realize which aspects of the model fall outside the bounds
of a given project and to determine what alternatives are
possible. This fine-tuning will become even more critical as
more complex regulations evolve and international regulations
diverge.
Lot Release Potency and Efficacy Assays
To ensure that a therapeutically effective dose of cells is admin-
istered as per recommendations, the manufacturing process for
allogenic cells or small molecule therapeutics requires that each
lot of cells or drug is similar to previous/subsequent lots and that
there are unambiguous tests to predict the activity of each batch.
Tests of this sort (Figure 2) and surrogate measures of efficacy
are routinely developed for drugs and will likely also be a regula-
tory requirement for cell therapy. In some cases, testable out-
comes may be obvious, such as glucose release from islet prep-
arations in response to insulin challenge. There are, however,
other proposed therapies for which the mechanism of action re-
mains unclear, or multiple modalities of action may occur. For
example, in some cases, MSCs may mediate a beneficial effect
in the treatment of stroke and infarcts, yet it is unclear how this
benefit is achieved, and it is thus difficult to define rigorous effi-
cacy or potency release criteria (or establish a dose range). Like-
wise, in spinal cord injury, transplanted cells have been pro-
posed to mediate myelination of demyelinated fibers. A rapid,
effective in vitro model that predicts myelination efficiency
in vivo does not yet exist for human cells. In cases of autologous
therapy, the lot size from a single individual may be too small to
spare enough cells from the final product to perform all of the
tests required. Therefore, context-specific flexibility in the en-
forcement of regulations will be important, provided that ensur-
ing the safety of patients remains paramount.22 Cell Stem Cell 4, January 9, 2009 ª2009 Elsevier Inc.
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AABB American Association of Blood Banks http://www.aabb.org/
AHCTA Alliance for Harmonisation of Cellular Therapy Accreditation http://www.ahcta.org/
ASBMT American Society for Blood and Marrow Transplantation http://www.asbmt.org/
CDER Center for Drug Evaluation and Research http://www.fda.gov/cder/
EBMT European Group for Blood and Marrow Transplantation http://www.ebmt.org/
EFI European Federation for Immunogenetics http://www.efiweb.eu/
EMEA European Medicines Agency http://www.emea.europa.eu/
ESRC Economic and Social Research Council http://www.esrc.ac.uk/
FACT Foundation for the Accreditation of Cellular Therapy http://www.factwebsite.org/
FDA U.S. Food and Drug Administration (see also CDER) http://www.fda.gov/
ICCBA International Council for Commonality in Blood Banking Automation, Inc. http://www.iccbba.org/
ISCT International Society for Cellular Therapy http://www.celltherapysociety.org/
ISSCR International Society for Stem Cell Research http://www.isscr.org/
JACIE Joint Accreditation Committee ISCT-EBMT http://www.jacie.org/
NSCB National Stem Cell Bank http://www.wicell.org/
UKSCB United Kingdom Stem Cell Bank http://www.ukstemcellbank.org/
WMDA World Marrow Donor Association http://www.worldmarrow.org/Acceptable Changes
An important challenge facing cell therapy is the need to define
a benchmark of ‘‘normal.’’ Various aspects of cells in culture or
in vivo are in constant flux, including changes in mitochondria,
methylation profiles, and other epigenetic changes as well as ge-
nomic changes (e.g., Maitra et al., 2005). Many of these changes
are of little consequence, but other more rare events such as
loss of a tumor suppressor or activation of an oncogene can be
highly significant in terms of both efficacy and safety. Both re-
searchers and regulatory authorities need to determine how to
distinguish trivial changes from potentially dangerous alterations,
and whether appropriate tests are available or even feasible.
Clearly, there is no consensuswithin the community on this score.
At one extreme, one could logically argue that transplanting autol-
ogous, minimally manipulated cells does not require safety tests,
given that the cells are normal for the recipient. In contrast, some
argue that evenwithout cell manipulation, the act of infusion itself,
or the transfer to an atypical environment, changes the dynamics
of theonce-normalcells (HalmeandKessler, 2006,and references
therein). Further, it is conceivable that a normal cell present in an
ectopic environmentmay have adverse consequences. Thus, de-
tailed testing should certainly be considered for any model of cell
therapy. Considering the large increase in the number of existing
or planned clinical trials to test cell therapy paradigms, the issue
of safety testing requires resolution—with some urgency.
Contamination from unwanted cells is yet another problem for
cell biologists transferring techniques to the clinic, which is
particularly important when a mixed population is used. Stem
cells are difficult to maintain as a reasonably pure population,
as they change over time. Cultures of neural stem cells, for ex-
ample, often contain contaminating glial cells. hESC samples,
even following directed differentiation, contain contaminating
populations of undifferentiated cells that themselves carry the
risk of unintended effects. The reality of population heterogeneity
is not a trivial issue and calls for major efforts to define consen-
sus standards of what level of impurity is acceptable in a given
cell preparation.Sorting and Selection Procedures
Generally there are no pure sources of stem cells, particularly of
stem cells present in limiting quantities. In addition, in many
cases the therapeutic candidate is the progeny of stem cells,
directed to differentiate in culture to acquire the characteristics
required to treat a particular disorder (reviewed by Magnus
et al., 2008). Sorting and selection procedures that isolate
stem cells or the differentiated progeny of choice are thus essen-
tial to most cell therapy models. Multiple methods have been de-
veloped includingmechanical sorting (size, surface charge, etc.),
selection based on differential growth requirements (glutamate,
serum, or other biological pathways that may be unique to cells)
or surface receptors (panning, magnetic-bead sorting, FACS,
etc.), or biological markers of stemness (e.g., enzyme activity or
uptake of dye). All of these processes involve amanipulation that
must be scalable and amenable to GMP procedures. This re-
quirement may not be trivial, as has been the experience with
FACS; the parts of the instrument in contact with cells cannot
be replaced or discarded easily, thus requiring extensive rede-
sign of the instrument. Likewise, beads and antibody selection
may leave a residue of bead fragments (e.g., Miltenyi beads) or
antibody (e.g., Dynal). In such cases, additional validation is re-
quired to preclude biological activity of the residue or unintended
alteration of the product function. Attention to this aspect of cell
manufacture is thus essential and needs to be attended to early
in the process, irrespective of whether the desired cell type is
a stem cell or a differentiated daughter.
Shipping, Freezing, and Tracking
Often-overlooked aspects of manufacturing products are the
shipping of the cells to the end user, and ensuring that the quality
and utility of the product are maintained during its transfer. It is
important to develop validated and quality-assured processes
to ship, track, and monitor the viability of the cell populations.
Validated processes are currently available for shipping at spe-
cific temperatures, but this may not be satisfactory for all cell
types. For instance,motor neuronsmay require live-cell shipping,Cell Stem Cell 4, January 9, 2009 ª2009 Elsevier Inc. 23
Cell Stem Cell
Perspectiveneed toarrivewithin acertain time frame, andneedbeusedwithin
a set period. In each case, extensive work will be required to
ensure the integrity of the packaging, the ability to maintain the
requisite environmental conditions to secure a healthy sample.
Historically, the development of a validated shipping practice
has taken many years. The blood bank industry and organ trans-
plant groupshave led the field todate, but it is clear that additional
effort must be undertaken by cell therapy advocates. The FDA,
EMEA, and others have some guidelines for acceptable viability
assays of cellular material. These assays include testing for the
number of viable cells, assessing how many cells were actually
delivered or retained after implantation, and compatibility with
the device used for delivering cells. Various regulatory agencies
have developed more-or-less uniform guidelines that convey
their intention to develop safe and effective therapies. However,
the guidelines need to be evaluated for each specific therapy to
determine if they place an undue or impossible burden on the
investigator.
We emphasize that while the above discussion has focused on
allogenic,manipulatedcells,manyof the issues, suchas theneed
for potency and efficacy assays, challenges in securing appropri-
ate shipping procedures, and measures of contamination, etc.,
are all equally relevant to autologous therapy models subject to
no or minimal processing.
Genetic Manipulation in Combination with Cell Therapy
More recently, attempts to obtain induced pluripotent stem cells
(iPSCs) that are patient specific have been significantly boosted
by genetic reprogramming (reviewed by Rao and Condic, 2008).
There is thus excitement in the field that combining genetic
manipulation with stem cell therapy will allow treatment of disor-
ders that simply could not be treated before. These combined
approaches may also allow us to resolve the immune issues of
cell transplantation by the development of patient-specific plurip-
otent lines. However, these cells currently present significant
technical and regulatory challenges that must be overcome be-
fore they can be used for the treatment of humans. Although the
use of retrovirally transformed cells is permitted in human clinical
trials, genetically modified cells carry a significant added burden
in regulatory approval. This is due to a need for demonstration
of the safety of methods of viral production, site of insertion,
and the genes inserted. In addition, difficulties in quality assur-
ance of autologous lots will add another level of difficulty for
achieving approval of an iPSC therapy. Although this is a direction
in which the field is and should be moving, we expect that the
regulatory hurdleswill be high. Induction of pluripotency in human
cells without genetic modifications would significantly ease this
concern.
Use of Banked Stem Cells Processed in Culture
For some cell/tissue-based products, immediate use or short-
term storage is possible. For other types (e.g., umbilical-cord
blood/placenta), the use is more prospective, thus generating
an inevitable need for long-term storage.
Banking of stem cells for future use represents a regulatory
challenge, and determining which regulations to apply is cur-
rently under debate. In line with our discussion above, it is clear
that banked cells are at least minimally processed, and thus any
subsequent use should be held to meet GMP guidelines, as with24 Cell Stem Cell 4, January 9, 2009 ª2009 Elsevier Inc.any other processed cell type. Another issue related to cell
manufacture and sourcing is also important: can a sample stored
under one set of regulations be transferred to another bank
covered by a different set of regulations? For example, could
a sample in a private umbilical-cord blood bank (originally des-
tined for use by a specific patient) that becomes obsolete be
instead used for an unrelated donation in a public bank, which
is regulated under a much more stringent set of manufacturing
regulations?
Applying GMP Practices to Cell Therapy
Based on the arguments presented above, it appears to us
that—overall—the cGMP model for biological compounds
(with some modifications taking into account unique issues re-
lated to cells) could be extended to allogeneic cell replacement
therapy. Skin replacement offers an example from a related field
and has succeeded in processing autologous cells to develop an
approved clinical product. Establishing a defined process may
help specific challenges within the issues discussed above,
such as sourcing variability, scalability, lot release, and potency
assays connected to a particular cell/tissue therapy. More signif-
icant changes to the standard GMP process development will
likely be required for adaptation of autologous-use models and
may be even more challenging in the case of storage banking
models for cell therapy. The critical point for all replacement ther-
apy, however, remains the same; ensuring that the regulations
themselves do not hinder the field, while still providing adequate
protection for recipients.
When does the ‘‘GMP process’’ need to be initiated in order to
ensure that onehas aclinically validated cell sample for use?With
respect to hESCs, does the derivation need to be performed at
a GMP-certified site, does the derivation have to be xenofree,
and can existing ESC lines be validated for clinical use? Although
it is difficult to provide unambiguous answers without extensive
data on the specific hESC line,webelieve that the following state-
ments are accurate. (1) The early phase of hESC derivation is
equivalent to obtaining tissue from a donor and is governed by
the Human Cells, Tissues, and Cellular and Tissue-Based Prod-
ucts (HTC/Ps) Act in the US and similar acts worldwide, and thus
does not require that the site beGMP validated. (2) Xeno compo-
nents present during the derivation process should be avoided
wherever possible but do not necessarily preclude obtaining val-
idation for clinical use. Products that contain xeno components
have been approved and remain in use today (e.g., heparin).
However, exposure to xeno compounds raises unique concerns,
and there are clear guidelines inmost countries formedical prod-
ucts. When applied to cell therapy, guidelines must demand ad-
ditional testing and validation for a particular hESC line if exposed
to xeno compounds. (3) Careful documentation, tracking, and
sterility controls will be needed, as described in the appropriate
guidance documents or acts (Hyun et al., 2008).
Indeed, Geron Corporation is in the process of filing an IND ap-
plication for clinical useof hESCs in theUS, andhasproposed the
use of an existing line derived in non-GMP certified in vitro fertil-
ization clinics and exposed to xenomaterial. No doubt regulation
will change as additional information from early studies becomes
available, but it is fair to say that cGMP practice does not pre-
clude the approval of cells derived in non-GMP environments
or exposed to xeno material.
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The issues discussed above relate to consent, source material,
manufacturing regulations, and choosing the most appropriate
recipient and underscore the need for regulatory advice and
uniform international standards. Science hasmade quite remark-
able progress, and many cell types are in early to late stage
clinical trials. The regulatory landscape is currently a patchwork
of regulations, often country specific and occasionally state or
region specific. Some countries have no finalized regulations or
an established body designated to hold regulatory authority
over the conduct of cell therapies. In some cases, nonprofit orga-
nizations have taken the lead in providing accreditation services.
The Alliance for Harmonisation of Cellular Therapy Accreditation
(AHCTA, which represents the Joint Accreditation Committee
ISCT-EBMT [JACIE], the European Group for Blood and Marrow
Transplantation [EBMT], the World Marrow Donor Association
[WMDA], the International Society for Cellular Therapy [ISCT],
ISCT-Europe, the Foundation for the Accreditation of Cellular
Therapy [FACT], FACT-Netcord, the European Federation for Im-
munogenetics [EFI], the American Society for Blood and Marrow
Transplantation [ASBMT], and theAmericanAssociationofBlood
Banks [AABB]) has proposed a minimal set of standards for har-
monization (Table 1). The document ‘‘Towards aGlobal Standard
for Donation, Procurement, Testing, and Distribution of HSC and
Related Cellular Therapies’’ includes minimal required testing of
the donor, a donor identification number, and an identification
of the tissue establishment. Tracking and tracing requirements
and product-labeling nomenclature are also included as well as
Figure 2. Battery of Assays for
Characterizing Embryonic Stem Cells for
Therapy
information on split number and expiry
date. Also, the ISBT 128 international in-
formation standard, set by the Interna-
tional Council for Commonality in Blood
Banking Automation, Inc. (ICCBBA, Inc.),
has provided a global standard over the
last decade for the identification, labeling,
and information processing of human
blood.
Consensus guidelines are also critical
to the development of quality control as-
sayswhen devising standards or generat-
ing universal reference data sets. When
adequate cellular material is available,
assays that might be required include
mRNA, microRNA, protein expression,
global patterns of methylation and chro-
matin modification, and, in the logical
extreme, complete sequencing of the
genome (see Figure 2), as determined af-
ter rigorous review by a panel of indepen-
dent experts. While these issues have
been discussed (e.g., Loring and Rao,
2006;Catalina et al., 2007) there is nocon-
sensus in the field.Consensuswouldaccelerateprogressand im-
prove global practice in stem cell research. The ISCF (Table 1) is
a collaboration of international funding agencies that produced
an international survey of hESC lines to provide a benchmark
for comparing results across laboratories (The International
Stem Cell Initiative, 2007). Similarly, MSC specialists convened
to develop a minimal set of properties that can be used to define
an MSC (Dominici et al., 2006). The ISSCR Stem Cell Standards
Committee (Table 1) offers another example of ongoing develop-
mentof international guidelinesandconsensusstandards in stem
cell research. The research project ‘‘Quality Assured Science:
The Role of Standards in Stem Cell Research’’ was set up by
The Economic and Social Research Council (ESRC) in the United
Kingdom (Table 1). Other initiatives in this field include the UK
Stem Cell Bank’s efforts to develop storage, deposit, and analy-
sis guidelines, and proposedminimal sets of information pertain-
ing to blastocysts used for the derivation of new embryonic stem
cell lines (Stephenson et al., 2006) (Table 1). In addition, the US
has initiated an extensive banking effort that includes aims to
standardize storage, culture, and differentiation conditions and
is in place at the National Stem Cell bank (NCSB) (see Table 1)
in Madison, WI.
Summary
In this commentary we highlight challenges related to cell sourc-
ing andmanufacturing of cellular products, all of which represent
timely issues, given the relatively rapid progress in this field. We
emphasize, however, that investigators face additional chal-
lenges, including obtaining reliable preclinical data in anCell Stem Cell 4, January 9, 2009 ª2009 Elsevier Inc. 25
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nally developing a satisfactory petition to the relevant regulatory
authorities. Without an approvable process, carrying out preclin-
ical studies will not yield data capable of justifying subsequent
clinical studies.
We note that outside the hematopoietic system and skin re-
placement therapies, very few investigators have had experience
in developing manufacturing processes or sourcing material in
cell therapy. Pharmaceutical companies have extensive experi-
ence in manufacturing small molecules and the like, and yet
most cell therapy applications are being led by researchers or
small biotechnology companies, for whom only limited expertise
is available.
We have tried to highlight what we think are general issues that
will affect cell therapy and have explained our rationale for why
we think they will be relevant concerns. We have deliberately
refrained from offering any specific solutions, as we feel that
any proposed action must be evaluated by multiple independent
reviews and by the appropriate regulatory bodies.We encourage
readers to initiate meetings with authorities to pose questions
and obtain feedback before initiating experiments.
SUPPLEMENTAL DATA
The Supplemental Data include two figures and can be found with this
article online at http://www.cell.com/cell-stem-cell/supplemental/S1934-
5909(08)00612-7.
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